Skip to main content
. Author manuscript; available in PMC: 2016 Aug 2.
Published in final edited form as: J Urol. 2015 Aug 29;195(2):313–320. doi: 10.1016/j.juro.2015.08.087

Figure 1. Status of PASS participants.

Figure 1

Participants are grouped according to whether they experienced adverse reclassification (an increase in biopsy Gleason grade and/or ratio of number of cores containing cancer to total number of cores from <34% to ≥34%) or had no reclassification. Participants with no reclassification are further divided into participants who had at least one repeat biopsy, and thus able to be reclassified, and those who had not yet had a repeat biopsy, and thus not able to be reclassified. Participants are further divided into those that are active (continuing to use active surveillance), had documented treatment, or inactive (left the study with no documentation of treatment).